As of May 23
| -0.0101 / -1.77%|
The 1 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 1.25, with a high estimate of 1.25 and a low estimate of 1.25. The median estimate represents a +123.21% increase from the last price of 0.56.
The current consensus among 2 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since May, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.